Clinical trialNCT04347239CompletedPhase 2Interventional

Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19

SponsorCytoDyn, Inc.Enrollment484Coronavirus Disease 2019

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study was assess the safety and efficacy of leronlimab (PRO 140) administered as weekly subcutaneous injection in subjects with severe or critical COVID-19 disease.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Jacob Lalezari, MD
CytoDyn, Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

18 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Advanced Cardiovascular, Llc
Alexander City, Alabama, United States
St. Jude Medical Center
Fullerton, California, United States
Ucla
Los Angeles, California, United States
James A. Haley Veterans' Hospital
Tampa, Florida, United States
Center for Advanced Research & Education (care)
Gainesville, Georgia, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
St. Barnabas
Livingston, New Jersey, United States
Atlantic Health System Hospital
Morristown, New Jersey, United States
Holy Name Medical Center
Teaneck, New Jersey, United States
New York Community Hospital of Brooklyn
Brooklyn, New York, United States
Montefiore Medical Center
The Bronx, New York, United States
Novant Health
Winston-Salem, North Carolina, United States
Ohio Health
Columbus, Ohio, United States
Good Samaritan Hospital Corvallis
Corvallis, Oregon, United States
Oregon Health and Sciences University
Portland, Oregon, United States
Baylor Scott & White Research Institute
Dallas, Texas, United States
Baylor College of Medicine
Houston, Texas, United States
University of Texas
Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

LeronlimabPlacebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 16 Apr 2020
Primary completion: 24 Oct 2021
Completion: 15 Jun 2022
Last update posted: 15 Oct 2025
Registered enrollment: 484
Registry id: NCT04347239

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.